grant
Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression
Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 6 Sept 2021Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025AbscissionAcuteAnti-Rejection TherapyAntibodiesBenefits and RisksBiological MarkersBloodBlood Reticuloendothelial SystemCalcineurin antagonistCalcineurin inhibitorCell BodyCellsCellular AssayChronic Kidney FailureChronic Renal DiseaseChronic Renal FailureClinicalClinical DataClinical TrialsCommunitiesComplicationDataDecision MakingDeteriorationDiagnosticDialysisDialysis procedureDiseaseDisorderDrug toxicityDrugsEarly DiagnosisEquilibriumExcisionExtirpationFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2FibrosisFutureGene ExpressionGenerationsGenomicsGlomerular Filtration RateGraft SurvivalHepatic TransplantationHypoxiaHypoxicImmuneImmune Cell ActivationImmune responseImmunesImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosuppressive TherapyInjury to KidneyInterventionKidneyKidney GraftingKidney TransplantationKidney TransplantsKidney Urinary SystemLiverLiver GraftingLiver TransplantMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMechanistic Target of RapamycinMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationModelingMonitorMulti-Institutional Clinical TrialMulti-center clinical trialMulti-center trialMulti-site clinical trialMulticenter TrialsMulticenter clinical trialMultisite clinical trialNMR ImagingNMR TomographyNephrotoxicNuclear Magnetic Resonance ImagingOutcomeOxygen DeficiencyPathway interactionsPatient SelectionPatientsPharmaceutical PreparationsPhenotypePhysiologicPhysiologicalPlasma ProteinsPropertyProteomicsRAFT1RandomizedRegimenRegulatory T-LymphocyteRemovalRenal GraftingRenal TransplantationRenal TransplantsRenal functionResearchResearch ResourcesResourcesRiskRoleSDZ RADSamplingScienceSurfaceSurgical RemovalT-CellsT-LymphocyteTacrolimusTeff cellTestingTherapeuticTherapeutic immunosuppressionTimeTransplant RecipientsTransplantationTransplanted Liver ComplicationTregWeaningWithdrawalWorkZeugmatographyartificial immunosuppressionbalancebalance functionbio-markersbiobankbiologic markerbiomarkerbiomarker performancebiomarker signaturebiomarker utilitybiomarker validationbiorepositorycell assaychronic kidney diseaseclinical practicecohortdialysis therapydrug/agentearly detectioneffector T celleverolimusexhaustionfrontierhepatic body systemhepatic organ systemhigh riskhost responseimaging biomarkerimaging markerimaging-based biological markerimaging-based biomarkerimaging-based markerimmune activationimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmunoresponseimmunosuppression therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinsightkidney functionkidney imagingkidney injurykidney ischemiakidney preservationkidney toxicitykidney txliver transplantationloss of functionmTORmTOR Inhibitormammalian target of rapamycinmarker validationmolecular biomarkermolecular diagnosticsmolecular markernephrotoxicitynew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetpathwaypatient stratificationpre-clinicalpreclinicalpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreservationpreventpreventingprimary end pointprimary endpointprimary outcomeprospectiveproteogenomicsrandomisationrandomizationrandomly assignedregulatory T-cellsrenalrenal injuryrenal ischemiaresectionresponserisk stratificationsample collectionsocial rolespecimen collectionstandard of carestratified patientstratify risktechnology platformtechnology systemthymus derived lymphocytetransplanttransplant patienttreatment strategyvalidation studies
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Project Summary/Abstract
The advent of molecular biomarkers holds great promise, both from a diagnostic perspective as well as the ability
to predict a disease state early enough to inform therapy and change clinical outcomes. In the last several years,
studies have suggested a role for biomarker profiling in the management of immunosuppression in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click